Johnson & Johnson (J&J) has sued drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs, and at least $25 million in damages from each defendant.
Patients complaining about receiving the wrong pills in their prescription bottles led J&J to discover widespread counterfeiting, as did the voluntary return of hundreds of bottles of counterfeit pharmaceuticals from one of the defendants, distributor ProPharma Distribution LLC.
Following Gilead Sciences Inc.'s lawsuit in January, the firm said it became aware of the sale of counterfeit versions of its HIV medications. Symtuza, a multi-drug combination treatment, as well as Prezcobix, Prezista, and Edurant, are among the medications at issue.
J&J claims that counterfeit bottles occasionally included a different HIV medicine than what was advertised on the label and that one counterfeit bottle contained the strong antipsychotic Seroquel.
The defendants include ProPharma, Safe Chain Solutions LLC, and Scripts Wholesale Inc, as well as drugstore operator I Care Pharmacy 14 and the business' individual proprietors.
According to the lawsuit, I Care Pharmacy had a physical location in New York City that was closed down immediately after a fraudulent transaction was found.
J&J believes the pharmacy is linked to a criminal counterfeiting network that is still operational in New York City, dispensing hazardous counterfeit HIV medication.


Gold Prices Fall as Stronger Dollar Weighs on Bullion
Rodrigo Duterte Makes First Public Appearance at ICC in 18 Months
Second DOJ Lawyer Exits Trump Probe
Kazakhstan and Tether Explore Tenge Stablecoin and RWA Tokenization
US Appeals Court Keeps Trump IRS Case Sanctions in Place
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash
Iceland 4x4 Rental Guide: When Do You Really Need Four-Wheel Drive?
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal
SpaceX Seeks $40 Billion for Nvidia AI Chips
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply
ICE Agent Arrested in Minneapolis Over Venezuelan Man Shooting
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents
Colombia Extradites FARC Dissident Leader ‘Spider’ to US
Ukraine Faces $56 Billion Budget Gap as War Costs Soar 



